Hot search: net  Processing  Machinery  income  operating  Auto  Automotive  power  Basin  electric 
 
Home > News > Market > Content

GSK Promacta Won FDA Approval as Thrombocytopenia Therapy in Chronic Hepatitis C Patients

increase font size  reduce font Add date: 2016-11-30  Hits:96
Core prompt: GlaxoSmithKline's (GSK) Promacta has won FDA approval as thrombocytopenia therapy in chronic hepatitis C patients.   Promacta,

GlaxoSmithKline's (GSK) Promacta has won FDA approval as thrombocytopenia therapy in chronic hepatitis C patients.

 

Promacta, brand name of eltrombopag in the US, will enable thrombocytopenia patients suffering from chronic hepatitis C to commence and sustain interferon-based therapy.

 

GlaxoSmithKline oncology president Paolo Paoletti said chronic hepatitis C is a significant public health issue.

 

"Some chronic hepatitis C patients suffer from low blood platelet counts. Commonly prescribed interferon-based therapies can worsen the problem of low blood platelet counts," Paoletti added.

 

"Today's FDA approval of PROMACTA gives doctors a tool to address the low platelet challenge. This means more chronic hepatitis C patients may be able to start and stay on interferon-based therapy."

 

The US regulatory body considered data from Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE (ENABLE) 1 and 2 Phase III studies conducted in patients with platelet counts less than 75,000/μL.

 

Promacta when combined with interferon-based therapy was proven to establish a constant virologic response or viral cure.

 

Thrombocytopenia is a condition in which a patient's blood contains a lower-than-normal number of platelets resulting in bleeding inside the body or beneath or from the skin.

 
 
[ NewsSearch ]  [ Send Fav ]  [ Share ]  [ Print ]  [ Send Report ]  [ Close ]

 
Total0bar [View All]  Related Comments

 
Photo Recommended
Recommend News
Click Rank
 
Home | Products | Suppliers | News | Tradeshow | Sitemap | Message | RSS Feed